Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $52.65, but opened at $51.05. Janux Therapeutics shares last traded at $50.67, with a volume of 128,178 shares changing hands.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the company. Cantor Fitzgerald started coverage on Janux Therapeutics in a research note on Wednesday, March 20th. They issued an "overweight" rating and a $100.00 price objective for the company. Bank of America lifted their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, March 13th. BTIG Research started coverage on Janux Therapeutics in a report on Thursday, March 21st. They issued a "buy" rating and a $62.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and set a $53.00 target price on shares of Janux Therapeutics in a report on Monday, March 11th. Finally, William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a research note on Tuesday, February 27th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of "Buy" and an average price target of $59.60.
View Our Latest Research Report on JANX
Janux Therapeutics Price Performance
The company has a fifty day moving average price of $32.00 and a 200 day moving average price of $17.11. The stock has a market cap of $2.68 billion, a P/E ratio of -38.70 and a beta of 4.19.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. The business had revenue of $2.46 million during the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Janux Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Janux Therapeutics by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 47,690 shares of the company's stock valued at $628,000 after buying an additional 1,127 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Janux Therapeutics by 4.5% in the 1st quarter. Rhumbline Advisers now owns 26,849 shares of the company's stock worth $325,000 after acquiring an additional 1,158 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in shares of Janux Therapeutics by 14.3% in the second quarter. State of Wisconsin Investment Board now owns 13,202 shares of the company's stock valued at $157,000 after purchasing an additional 1,647 shares during the last quarter. American International Group Inc. lifted its position in shares of Janux Therapeutics by 25.3% during the first quarter. American International Group Inc. now owns 8,813 shares of the company's stock valued at $126,000 after purchasing an additional 1,782 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Janux Therapeutics by 149.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company's stock worth $40,000 after purchasing an additional 2,003 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.
About Janux Therapeutics
(
Get Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Featured Articles
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
